nanoparticl
includ
lipopolyamin
lead
lipoplex
liposom
polyplex
target
drug
carrier
system
current
search
success
deliveri
system
polynucl
acid
review
focus
impact
gene
sirna
deliveri
studi
efficaci
pharmacodynam
pharmacokinet
within
set
wide
varieti
vivo
anim
model
use
critic
apprais
recent
literatur
set
differ
model
current
investig
bridg
studi
cell
line
toward
clinic
realiti
whilst
mani
scientist
familiar
rodent
murin
fecin
cricetin
mustelin
model
probabl
think
fish
clinic
relev
anim
model
zebrafish
madak
rainbow
trout
use
larger
anim
model
includ
rabbit
cat
dog
cow
pig
use
prevent
footandmouth
diseas
human
diseas
sheep
model
corneal
transplant
hors
natur
develop
arthriti
nonhuman
primat
model
macaqu
common
marmoset
owl
monkey
use
preclin
gene
vector
safeti
efficaci
trial
bridg
gap
prior
clinic
studi
aim
safe
develop
clinic
effect
deliveri
system
dna
rnai
technolog
gene
therapi
consist
modif
gene
express
therapeut
gain
depend
understand
basic
biolog
principl
mani
gene
therapi
studi
correct
gene
insert
genom
replac
abnorm
diseasecaus
gene
fig
carrier
vector
must
use
deliv
therapeut
gene
patient
target
cell
common
vector
virus
genet
alter
carri
normal
human
dna
virus
attack
host
introduc
genet
materi
host
cell
part
replic
cycl
therefor
use
vehicl
carri
good
gene
human
cell
numer
problem
exist
lessen
likelihood
success
gene
therapi
use
viral
vector
mani
undesir
effect
vector
often
toxic
immunogen
hard
ensur
viru
infect
target
cell
bodi
insert
gene
must
disrupt
vital
gene
alreadi
genom
howev
compani
persist
method
gene
introduct
also
nonvir
method
gene
therapi
although
low
level
transfect
gene
express
mean
nonvir
vector
still
less
effici
present
certain
advantag
viral
method
simpl
larg
scale
product
low
host
immunogen
two
recent
advanc
nonvir
cation
lipid
vector
technolog
yield
molecul
techniqu
transfect
effici
similar
achiev
virus
modern
nonvir
method
plasmid
dna
coat
lipid
organ
structur
lipoplex
polyplex
cation
polym
fig
small
interf
rna
sirna
signal
cell
cleav
specif
sequenc
mrna
transcript
faulti
gene
disrupt
translat
therefor
silenc
express
gene
theori
transform
either
somat
cell
cell
germlin
possibl
gene
therapi
date
human
direct
somat
cell
wherea
germlin
engin
human
rightli
remain
controversi
last
two
decad
gene
transfer
experi
treatment
inherit
acquir
diseas
perform
gene
therapi
move
preclin
clinic
studi
mani
diseas
rang
singl
gene
disord
cystic
fibrosi
duchenn
muscular
dystrophi
complex
diseas
cancer
cardiovascular
disord
better
understand
structur
function
human
gene
develop
new
strategi
order
combat
diseas
compar
human
genom
genom
organ
identifi
region
similar
differ
compar
genom
studi
found
dna
sequenc
similar
human
mice
http
wwwornlgovscitechresour
ceshumangenomefaqcompgenshtml
lot
key
variat
eg
mous
human
gene
product
almost
ident
other
nearli
unrecogniz
close
rel
dog
http
wwwhomeearthlinknet
pig
cat
primat
share
genom
among
known
gene
cattl
could
identifi
ident
human
gene
http
wwwscienceblogcomcommun
rabbit
chromosom
paint
except
paint
hybrid
human
chromosom
human
chromosom
paint
except
paint
hybrid
rabbit
chromosom
chimpanze
dna
sequenc
ident
http
www
genomegov
fruit
fli
genom
human
genom
gene
common
http
nesbbccouk
also
share
half
gene
banana
http
wwwwasdarwin
rightcomhomologyhtm
anim
model
human
diseas
import
develop
assess
gene
therapi
particularli
evid
evalu
gene
therapi
protocol
clinic
trial
gene
transfer
studi
statist
ration
meaning
outcom
need
evalu
model
close
resembl
human
diseas
anim
model
clearli
import
step
preclin
evalu
humandirect
gene
transfer
protocol
possibl
human
ethic
lack
volunt
reason
rna
interfer
rnai
alreadi
recogn
function
genom
research
tool
mammalian
gene
knockdown
studi
target
discoveri
valid
show
great
diagnost
therapeut
potenti
fig
cours
could
huge
commerci
potenti
gene
therapi
product
reason
biotechnolog
pharmaceut
compani
invest
develop
gene
therapi
rnai
technolog
could
reduc
time
need
target
valid
drug
develop
acceler
drug
discoveri
process
rnaibas
screen
provid
new
opportun
discoveri
valid
novel
therapeut
target
sever
diseas
area
eg
cancer
infecti
diseas
signific
effect
oligonucleotid
diseas
phenotyp
indic
target
question
play
import
role
diseas
state
potent
rnai
compound
provid
import
tool
vivo
valid
administ
anim
model
diseas
order
determin
inhibit
express
result
correspond
vivo
chang
diseas
phenotyp
rnai
knockdown
model
produc
fraction
time
cost
requir
previou
antisens
knockout
mous
technolog
remark
short
order
larg
replac
rnaibas
system
precis
select
mechan
sirna
action
reduc
potenti
sideeffect
offtarget
effect
deliveri
intracellular
stabil
sirna
agent
major
hurdl
translat
emerg
technolog
commerci
viabl
therapeut
involv
consider
compet
technolog
safeti
efficaci
regulatori
issu
rnai
therapeut
studi
treatment
agerel
macular
degener
amd
cancer
infect
influenza
cardiovascular
cn
metabol
disord
specif
target
includ
hypercholesterolemia
respiratori
diseas
metabol
diseas
hepat
c
viru
hcv
liver
liver
cancer
gene
target
treatment
renal
failur
hope
treatment
neurodegen
diseas
parkinson
diseas
progress
multifoc
leukoencephalopathi
pml
caus
infect
cn
jc
viru
occur
immunesuppress
patient
includ
receiv
immunomodulatori
therapi
target
huntington
diseas
gene
deliv
medtron
implant
infus
pump
technolog
free
deliveri
problem
safeti
issu
accur
anim
model
exist
help
answer
import
question
review
ten
differ
anim
model
use
answer
key
question
efficaci
pharmacodynam
pharmacokinet
model
prior
clinic
trial
gene
therapi
like
administr
new
drug
test
anim
model
clinic
applic
human
earli
anim
model
gene
therapi
focuss
upon
simul
inherit
genet
disord
judg
appropri
candid
earli
human
trial
base
heavili
upon
molecular
medicin
anim
genet
engin
reflect
diseas
state
transgen
anim
use
model
differ
human
diseas
infect
neurodegener
apoptosi
arteriosclerosi
age
cancer
xenograft
etc
one
goal
use
model
assess
potenti
efficaci
genet
intervent
evalu
impact
meaning
surrog
clinic
endpoint
clearli
gene
transfer
experi
perform
mice
larg
anim
model
pig
hors
almost
exclus
use
studi
treatment
induc
diseas
cardiovascular
diseas
arthriti
respect
sheep
nonhuman
primat
use
develop
gene
transfer
techniqu
gene
mark
studi
assess
safeti
despit
exist
genet
diseas
speci
yet
use
treatment
trial
howev
aspect
human
popul
imposs
simul
anim
model
tremend
environment
genet
divers
particularli
import
context
immun
respons
gene
replac
therapi
sever
factor
may
profoundli
contribut
outcom
natur
mutat
diseas
gene
major
histocompat
genotyp
previou
exposur
recipi
deliveri
vehicl
context
natur
acquir
infect
epstein
barr
viru
ebv
associ
increas
number
lymphoid
epitheli
malign
among
gene
express
ebv
latenc
play
key
role
growth
transform
immort
b
lymphocyt
eleg
studi
dept
public
health
scienc
univers
la
sapienza
rome
galletti
et
al
shown
antisens
oligonucleotid
on
direct
mrna
effect
suppress
gene
express
substanti
reduc
prolifer
infect
cell
use
marmoset
cell
line
use
antisens
phosphodiest
oligonucleotid
therapeut
agent
limit
ineffici
cellular
uptak
intracellular
transport
target
mrna
therefor
test
abil
three
cation
carrier
intern
differ
pathway
increas
deliveri
site
action
ebvinfect
b
lymphocyt
liposom
dendrim
transferrinpolylysineconjug
intern
cell
extent
severalfold
higher
nake
oligom
howev
deliveri
system
exploit
transferringreceptor
mediat
pathway
abl
vector
biolog
activ
antisens
cell
line
studi
typifi
lot
current
pharmaceut
research
nonvir
gene
therapi
work
dna
condens
celllin
transfect
similarli
pois
make
transit
anim
model
target
diseas
gene
therapi
probabl
think
fish
piscin
model
clinic
relev
anim
model
howev
zebrafish
danio
rerio
medaka
oryzia
latip
use
initi
model
gene
deliveri
even
anim
model
human
diseas
eg
hepat
diseas
cancer
rainbow
trout
oncorhynchu
mykiss
model
also
use
zebrafish
good
model
better
understand
congenit
diseas
achromatopsia
campomel
dysplasia
defect
neural
crest
develop
signific
caus
human
diseas
one
waardenburg
syndrom
neurocristopathi
individu
domin
pigment
defect
loss
specif
cone
type
caus
partial
colour
blind
wherea
gener
loss
cone
function
caus
total
colour
blind
macular
degener
anoth
relat
deaf
medaka
fish
model
studi
organogenesi
process
haemoglobinbilirubin
metabol
function
receptor
rainbow
trout
adjuv
effect
earli
respons
viral
hemorrhag
septicemia
viru
vhsv
immun
investig
dna
vaccin
fish
rhabdoviru
vhsv
use
express
plasmid
code
viral
glycoprotein
coadminist
clone
interleukin
specif
rout
deliveri
effici
use
adjuv
investig
import
rodent
murin
fecin
cricetin
mustelin
model
dna
sirna
deliveri
strategi
selfevid
number
murin
mous
rat
model
depend
assumpt
biolog
process
close
resembl
human
also
inexpens
keep
gener
time
short
larg
litter
howev
murin
model
may
fail
mirror
faith
human
diseas
longitudin
studi
possibl
short
lifespan
thu
larg
anim
model
human
genet
diseas
complement
murin
studi
longer
lifespan
similar
size
neonat
child
background
genet
heterogen
similar
human
genet
close
relat
human
mice
mice
still
use
studi
mani
differ
diseas
eg
cancer
haemophilia
neurolog
diseas
scid
duchenn
muscular
dystrophi
mani
other
model
provid
us
differenti
tissu
often
avail
human
sourc
furthermor
allow
test
effect
genet
manipul
experiment
therapeut
physiolog
patholog
duchenn
muscular
dystrophi
mutat
dystrophin
gene
occur
region
encod
spectrinlik
central
rod
domain
splice
around
mutat
gener
shorten
infram
transcript
therebi
permit
translat
partial
function
dystrophin
protein
test
vivo
dystroph
mous
carri
mutat
exon
dystrophin
gene
treat
mice
show
persist
product
dystrophin
normal
level
larg
number
muscl
fibr
function
improv
treat
muscl
common
lethal
genet
diseas
caucasian
popul
cystic
fibrosi
cf
cf
monogen
diseas
whose
phenotyp
variabl
attribut
genet
variat
modifi
gene
sever
research
group
interrupt
incorpor
specif
mutat
cf
transmembran
conduct
regul
gene
cftr
lethal
gastrointestin
manifest
diseas
prevent
introduc
germ
line
cf
mous
transgen
encod
human
cftr
express
gutspecif
promot
sever
studi
demonstr
effici
vivo
deliveri
sirna
first
direct
deliveri
sirna
vivo
carri
use
hydrodynam
techniqu
administ
nake
sirna
larg
volum
physiolog
solut
high
pressur
tail
vein
mice
order
evalu
efficaci
deliveri
method
mice
coinject
plasmid
express
luciferas
gene
report
along
synthet
prepar
sirna
target
luciferas
mrna
fig
gene
transfer
experi
perform
mice
earli
model
switch
cell
line
vivo
use
hydrodynam
deliveri
tail
vein
mous
recent
evid
sirna
better
shrna
encod
plasmid
dna
vivo
knockdown
liver
fibrosi
induc
ccl
bile
duct
ligat
amelior
adenovir
gene
transfer
matrix
metalloproteinas
human
neutrophil
collagenas
rat
model
earlier
adenovir
gene
transfer
human
urokinasetyp
plasminogen
activ
upa
also
revers
experiment
rat
liver
fibrosi
induc
collagenas
express
gene
deliveri
interstiti
collagenas
promis
treatment
advanc
cirrhosi
human
howev
persist
overexpress
interstiti
collagenas
liver
possibl
digest
normal
architectur
addit
patholog
deposit
ecm
therefor
precis
control
deliveri
activ
interstiti
mmp
may
necessari
develop
clinic
treatment
regard
treat
genet
blind
anim
model
leber
congenit
amaurosi
lca
lrat
mous
clinic
featur
human
diseas
intraocular
inject
raavdeliv
lrat
gene
therapi
oral
pharmacolog
treatment
novel
acet
succin
easier
synthes
stabl
replac
success
restor
electroretinograph
respons
wildtyp
level
p
versu
wildtyp
knockout
control
pupillari
light
respons
lrat
mice
also
increas
log
unit
therapeut
util
cytochrom
enzym
prodrug
therapi
well
establish
preclin
studi
initi
clinic
trial
underli
premis
gene
therapi
intratumour
express
lead
situ
activ
anticanc
prodrug
cyclophosphamid
cpa
intratumour
accumul
activ
metabolit
favour
pharmacokinet
shown
mice
bear
gliosarcoma
subcutan
solid
tumour
vivo
model
inoper
pancreat
carcinoma
express
therefor
advantag
gene
therapi
strategi
combin
low
k
prodrug
activ
enzym
slow
local
releas
prodrug
substrat
recent
work
waxman
colleagu
boston
univers
follow
report
pharmacokinet
studi
reductas
cpa
activ
rat
cancer
gene
therapi
model
establish
nonvir
gene
deliveri
system
intraven
administr
complex
pdna
pll
pei
block
copolym
test
vivo
turnov
studi
polyion
complex
micel
selfassembl
coreshel
structur
yield
spheric
nanoparticl
administ
iv
male
balbc
mice
part
pharmacokinet
studi
cardiovascular
research
though
target
ligand
micel
effici
transfect
cell
micel
inject
via
supramesenter
vein
express
gene
observ
liver
sustain
day
conclud
gene
deliveri
system
intrins
effici
immunotherapi
potent
treatment
cancer
danger
sideeffect
stand
way
progress
pharmacokinet
safeti
evalu
use
mice
cynomolgu
monkey
perform
lipoplex
encod
human
norman
parker
colleagu
vical
support
phase
human
cancer
therapi
clinic
trial
kissel
cowork
depart
pharmaceut
biopharmaci
marburg
long
studi
pei
order
make
dna
polyplex
effici
show
dna
condens
measur
ethidium
bromid
fluoresc
quench
assay
optim
compar
transfect
effici
result
variou
differ
cell
line
pharmacokinet
biodistribut
mice
approxim
half
inject
dose
accumul
liver
demonstr
low
molecular
weight
pei
better
less
toxic
higher
transfect
effici
pei
high
molecular
weight
rnai
knock
oncogen
cancer
includ
brain
cancer
therapeut
potenti
rnai
realis
ratelimit
step
deliveri
solv
view
develop
rnabas
therapeut
practic
due
instabl
rna
vivo
howev
plasmid
dna
engin
express
short
hairpin
rna
shrna
similar
endogen
microrna
new
iv
nonvir
rnaibas
gene
therapi
new
genetarget
technolog
encapsul
pdna
insid
receptorspecif
pegyl
immunoliposom
pil
feasibl
rnai
approach
evalu
show
possibl
achiev
knockdown
brain
tumourspecif
gene
express
singl
intraven
inject
adult
mice
rat
intracrani
human
brain
cancer
surviv
mice
extend
nearli
weekli
intraven
inject
pil
carri
pdna
express
shrna
direct
human
epiderm
growth
factor
receptor
rnaibas
gene
therapi
coupl
gene
therapi
replac
mutat
tumour
suppressor
gene
build
polygen
approach
gene
therapi
cancer
adenovirus
ad
robust
gene
deliveri
vector
vivo
limit
propens
provok
strong
innat
adapt
respons
peg
modif
spapeg
adenoviru
protect
vector
preexist
adapt
immun
respons
reduc
proteinprotein
interact
interact
immun
cell
note
increas
pegyl
ad
vector
ablat
vitro
transduct
surprisingli
neg
effect
level
distribut
vivo
gene
deliveri
possibl
via
heparin
sulfat
integrin
interact
pegyl
reduc
innat
immun
respons
without
reduc
transduct
vivo
nonspecif
vector
uptak
macrophag
kupffer
cell
may
critic
involv
initi
activ
innat
immun
respons
earli
studi
use
direct
inject
admedi
gene
deliveri
guinea
pig
fecin
model
admedi
deliveri
rnai
also
recent
afford
new
antifootandmouth
data
guinea
pig
pig
compar
studi
male
femal
guinea
pig
g
larg
white
swine
kg
use
perform
viral
challeng
gerbil
hamster
cricetin
model
also
use
admedi
gene
transfer
fibroblast
growth
increas
brduposit
cell
forebrain
ischemia
gerbil
admedi
overexpress
gene
prevent
hear
loss
progress
inner
hair
cell
loss
transient
cochlear
ischemia
gerbil
raav
type
show
distinct
pattern
gene
transfer
gerbil
hippocampu
raavtransduc
vascular
endotheli
cell
express
thrombomodulin
transgen
regul
enhanc
plasminogen
activ
promot
mongolian
gerbil
type
protein
phosphatas
overactiv
fail
heart
depress
cardiac
function
vivo
inhibit
myocardi
gene
transfer
endogen
inhibitor
allevi
heart
failur
hf
progress
cardiomyopath
hamster
wellestablish
hf
model
aavmedi
gene
deliveri
improv
fraction
shorten
left
ventricl
accompani
reduc
chamber
size
week
aavmedi
gene
deliveri
significantli
extend
surviv
time
month
result
provid
potenti
new
treatment
hf
without
activ
protein
kinas
signal
cardiomyocyt
limb
girdl
muscular
dystrophi
lgmd
genet
phenotyp
heterogen
group
degen
neuromuscular
diseas
subset
genet
recess
form
lgmd
caus
mutat
four
muscl
sarcoglycan
gene
alpha
beta
gamma
delta
code
sequenc
known
sarcoglycan
gene
smaller
kb
thu
readili
packag
raavvector
effici
deliveri
hamster
model
bio
singl
intramuscular
inject
result
support
feasibl
raavvector
mediat
deliveri
treat
lgmd
direct
vivo
gene
transfer
earli
studi
ferret
mustelin
model
use
show
protect
influenza
challeng
dna
vaccin
haemagglutinin
gene
gun
deliveri
dnacoat
gold
particl
recent
engelhardt
cowork
report
compar
biolog
raav
transduct
ferret
pig
human
airway
epitheli
cell
well
improv
relat
anim
model
famili
hypercholesterolemia
fh
inherit
disord
human
caus
defici
low
densiti
lipoprotein
receptor
ldlr
rabbit
lapin
model
watanab
herit
hyperlipidem
use
model
fh
order
develop
approach
liverdirect
gene
therapi
base
transplant
autolog
hepatocyt
genet
correct
ex
vivo
recombin
retrovirus
rabbit
transplant
ldlrtransduc
autolog
hepatocyt
demonstr
decreas
total
serum
cholesterol
persist
durat
experi
recombinantderiv
ldlr
rna
harvest
tissu
diminut
month
transplant
rabbit
also
use
studi
heart
diseas
use
percutan
catheterbas
approach
select
intracoronari
arteri
deliveri
adult
new
zealand
rabbit
variou
procedur
test
optim
adenovirusmedi
gene
transfer
effici
includ
pharmacolog
pretreat
increas
vessel
permeabl
transient
interrupt
coronari
flow
highpressur
deliveri
coronari
venou
sinu
occlus
studi
aim
construct
recombin
plasmid
observ
effect
vascular
endotheli
growth
factor
gene
therapi
bone
defect
new
zealand
white
rabbit
oryctolagu
cuniculu
plasmid
inject
injur
site
one
foreleg
bone
defect
experi
group
physiolog
salin
solut
inject
opposit
foreleg
control
group
week
oper
xray
taken
observ
repair
heal
bone
defect
fig
mrna
express
low
level
week
reach
peak
week
decreas
normal
level
week
week
bone
heal
new
bone
observ
heme
sensit
reliabl
indic
cellular
oxid
stress
benefici
therapeut
applic
human
ho
gene
transfer
gene
therapi
varieti
clinic
circumst
ho
gene
must
deliv
safe
vector
adenovir
retrovir
leptosom
base
vector
current
use
clinic
trial
except
ho
gene
deliveri
either
ocular
cardiovascular
tissu
via
catheterbas
deliveri
system
ho
deliveri
must
site
organ
specif
achiev
rabbit
ocular
tissu
rat
liver
kidney
vasculatur
spontan
hypertens
rat
shr
kidney
cat
particular
interest
neurolog
disord
brain
well
character
function
physiolog
anatomi
cat
brain
similar
human
lysosom
storag
diseas
good
candid
cn
gene
therapi
activ
enzym
genet
correct
cell
secret
taken
surround
diseas
cell
small
amount
enzym
normal
requir
revers
storag
lesion
gene
therapi
evalu
brain
cat
affect
amd
lysosom
storag
diseas
caus
defici
lysosom
laman
activ
via
vector
diseas
cat
caus
bp
delet
felin
gene
fmanb
character
clinic
sign
neuropatholog
biochem
abnorm
similar
seen
human
patient
magnet
reson
imag
mri
perform
anesthet
cat
treat
cat
show
signal
intens
cerebr
white
matter
reduc
fig
howev
improv
cellular
storag
even
larg
distanc
transduct
site
seen
perhap
due
diffus
small
quantiti
lanam
inject
site
distant
brain
region
altern
method
enzym
distribut
axon
transport
circul
cerebrospin
fluid
studi
show
somat
gene
transfer
cn
deliv
function
enzym
directli
defici
brain
cell
without
high
morbid
mortal
rate
associ
bone
marrow
transplant
genet
diseas
present
dog
true
orthologu
human
diseas
caus
mutat
gene
addit
obviou
longev
similar
size
small
child
mani
part
canin
immun
system
similar
human
mucopolysaccharidosi
vii
mp
vii
sli
syndrom
defici
inherit
lysosom
storag
disord
caus
defici
activ
requir
catabol
glycosaminoglycan
whose
accumul
cv
cell
lead
cardiac
disord
also
cn
diseas
haskin
wolf
cowork
univers
pennsylvania
make
major
contribut
research
area
first
anim
model
mp
vii
describ
german
shepherd
dog
cdna
sequenc
known
mutat
identifi
experi
test
intraven
retrovir
rv
vector
neonat
dog
day
life
signific
improv
growth
treat
dog
skelet
diseas
treat
limb
week
age
percent
normal
enzym
activ
peripher
white
blood
cell
contain
vector
sequenc
low
compar
neonat
treat
dog
may
help
explain
benefit
earlier
treatment
hemophilia
b
also
studi
dog
xlink
inherit
bleed
disord
caus
defici
blood
clot
factor
respons
bleed
crise
canin
model
haemophilia
use
develop
evalu
gene
therapi
canin
protein
well
character
gene
clone
cdna
avail
although
vectorassoci
toxic
fig
remain
obstacl
singl
inject
hdv
led
longterm
transgen
express
vector
persist
two
fviiidefici
anim
convers
sever
phenotyp
moder
one
overal
biolog
behaviour
malign
melanoma
similar
dog
human
therefor
dog
ideal
model
develop
therapi
cancer
trial
canin
oral
melanoma
liposom
conjug
fasligand
dna
inject
directli
tumour
induc
apoptosi
tumour
regress
observ
three
five
treat
dog
local
system
advers
effect
observ
cours
observ
period
fig
complet
reliabl
infiltr
entir
prostat
import
improv
efficaci
intraprostat
gene
therapi
well
drug
deliveri
optim
inject
scheme
feasibl
magnet
reson
imag
mri
evalu
orthotop
canin
model
mri
use
gadoliniumdiethylenetriamin
pentaacet
acid
excel
modal
evalu
effect
volum
distribut
inject
vivo
orthotop
prostat
model
leber
congenit
amaurosi
lca
heterogen
earlyonset
retin
dystrophi
account
inherit
congenit
blind
one
caus
lca
loss
enzym
lecithinretinol
acyl
transferas
lrat
requir
regener
visual
photopig
retina
lca
earlyonset
sever
retin
dystrophi
eosrd
genet
heterogen
retin
pigment
epithelium
gene
defect
lca
caus
near
total
blind
infanc
natur
occur
anim
model
dog
suffer
earli
sever
visual
impair
similar
seen
human
lca
gene
therapi
correct
genet
defect
dog
abl
walk
maze
demonstr
improv
vision
visual
function
restor
anim
model
childhood
blind
raav
deliveri
wildtyp
diseas
genet
compon
mani
scientist
concern
go
blind
cure
outstand
work
ali
bainbridg
moor
colleagu
moorfield
eye
hospit
divis
inherit
eye
diseas
ucl
make
real
progress
possibl
clinic
advanc
topic
cover
review
first
gene
therapi
eye
trial
human
earli
onset
retin
dystrophi
result
mutat
start
success
result
first
three
adult
patient
present
month
plan
enrol
eight
patient
year
success
treatment
genet
disord
lrat
defici
follow
work
human
eventu
make
refere
paper
week
frontpag
stori
three
major
uk
newspap
steven
howarth
bolton
recov
sight
enough
walk
home
night
true
peer
review
calv
weigh
kg
birth
similar
weight
child
make
good
model
address
scalingup
issu
therapi
design
older
children
use
model
urea
cycl
defect
like
citrullinemia
primari
caus
hyperammonemia
pediatr
popul
associ
high
neurolog
morbid
fig
mortal
citrullinemia
caus
nonsens
mutat
c
transit
gene
code
arginosuccin
synthetas
cattl
although
mani
clinic
sign
control
dietari
restrict
protein
addit
ill
easili
result
hyperammonemia
studi
urea
cycl
defect
two
neonat
calv
receiv
adenoviru
contain
human
arginosuccin
synthetas
cdna
intraven
week
administr
adenoviru
calv
elev
serum
aspartateaminotransferas
concentr
whilst
liver
paramet
remain
normal
time
point
gene
therapi
could
good
antiarrhythm
strategi
arrhythmia
abnorm
heartbeat
type
fast
slow
irregular
heart
handl
minut
acceler
heartbeat
repeat
episod
caus
heart
failur
heart
simpli
weak
pump
blood
properli
lead
dizzi
collaps
death
genet
modif
atrioventricular
node
investig
intracoronari
perfus
model
heart
arrhythmia
pig
gene
therapi
use
method
porcin
heart
infect
rad
express
escherichia
coli
adg
ad
encod
subunit
hypothesi
excess
would
mimic
effect
antagonist
effect
creat
local
overexpress
suppress
baselin
atrioventricular
conduct
slow
heart
rate
atrial
fibril
without
produc
complet
heart
block
contrast
express
report
gene
electrophysiolog
effect
one
week
treatment
anim
kill
organ
remov
histolog
evalu
fig
differ
rodent
human
airway
cell
biolog
made
difficult
translat
recombin
adenoassoci
viru
raav
mediat
gene
therapi
lung
cystic
fibrosi
cf
new
ferret
pig
model
cf
becom
avail
engelhardt
cowork
knowledg
host
cellvector
interact
speci
becom
increasingli
import
test
potenti
gene
therapi
nlink
sialic
acid
receptor
requir
transduct
human
mous
airway
epithelia
ferret
pig
airway
epithelia
henc
although
airway
tropism
raav
serotyp
conserv
better
among
ferret
pig
human
compar
mous
viral
receptorscoreceptor
appear
maintain
consider
speci
divers
pig
use
medicin
research
develop
also
new
plasmidmedi
approach
supplement
pig
somatotropin
product
report
worker
advisi
texa
admedi
gene
transfer
hyperpolarizationactiv
cyclic
nucleotideg
cation
channel
creat
genet
pacemak
pig
complet
atrioventricular
block
search
cure
sitespecif
gene
therapi
experiment
cardiac
bradyarrhythmia
hydrodynam
gene
deliveri
attract
option
nonvir
liver
gene
therapi
approach
requir
evalu
efficaci
safeti
clinic
applic
techniqu
larg
anim
model
fabr
et
al
evalu
retrograd
deliveri
dna
whole
liver
via
isol
segment
inferior
vena
cava
ivc
drain
hepat
vein
use
pig
kg
given
via
two
programm
syring
pump
parallel
interspeci
comparison
rat
hydrodynam
procedur
gener
intrahepat
vascular
pressur
mmhg
approxim
four
time
higher
rodent
level
gene
deliveri
approxim
lower
clinic
accept
approach
liver
gene
therapi
howev
less
effect
pig
rodent
possibl
larger
liver
size
less
compliant
connect
tissu
framework
cornerston
effici
cardiac
gene
therapi
need
vector
system
enabl
select
longterm
express
gene
interest
rodent
anim
model
aav
vector
like
shown
effici
transduc
cardiomyocyt
howev
sinc
signific
speciesdepend
differ
transduct
characterist
exist
larg
anim
model
immin
need
preclin
evalu
raak
cowork
compar
gene
transfer
effici
heparin
bind
sitedelet
vector
pig
model
pressureregul
retroinfus
anterior
interventricular
cardiac
vein
previous
shown
deliv
gene
effici
myocardium
viral
genom
per
anim
vector
luciferas
report
gene
cytomegaloviru
cmv
enhanc
kb
rat
myosin
light
chain
promot
control
substanti
increas
report
gene
express
target
distal
left
anterior
descend
lad
territori
retroinfus
vector
show
lower
transgen
express
could
increas
coadministr
recombin
human
vegf
signific
transgen
express
detect
organ
heart
although
vector
genom
detect
also
lung
liver
thu
show
effici
longterm
myocardi
report
gene
express
target
lad
area
porcin
heart
genet
modif
cell
anim
invalu
tool
biotechnolog
biomedicin
worker
fig
measur
gene
transfer
efficaci
xgal
stain
transvers
section
av
groov
cell
express
stain
blue
b
western
blot
av
nodal
tissu
demonstr
overexpress
adg
infect
anim
c
gross
microscop
patholog
exposur
liver
kidney
ovari
xgal
solut
reprint
permiss
macmillan
publish
ltd
natur
medicin
copyright
depart
surgic
scienc
univers
milano
recent
report
result
genet
modifi
pig
foetus
deliv
embryo
spermmedi
gene
transfer
method
integr
vector
may
lead
insert
mutagenesi
variabl
transgen
express
undergo
silenc
nonvir
vector
prefer
scaffoldmatrix
attach
regionbas
nonvir
express
system
pepi
replic
autonom
mammalian
cell
may
enabl
safe
reliabl
genet
modif
higher
eukaryot
cell
organ
result
import
absenc
mosaic
import
step
forward
anim
transgenesi
biomed
applic
might
provid
basi
futur
develop
germlin
gene
therapi
pill
cowork
safeti
assess
studi
gsk
ware
report
particlemedi
dna
deliveri
dna
vaccin
hepat
b
minipig
determin
toxic
small
number
phagocytos
gold
particl
biodistribut
pdna
present
day
day
clear
minipig
regard
good
model
human
data
support
hypothesi
particlemedi
dna
deliveri
safe
human
clinic
applic
pig
rhesu
macaqu
good
model
effort
improv
dna
vaccin
immun
potenc
gene
deliveri
electropor
studi
pdna
deliveri
target
tissu
name
skin
hirao
et
al
school
medicin
univers
pennsylvania
studi
effect
electropor
high
plasmid
concentr
result
improv
gene
express
pgfp
deliv
intradermalsubcutan
idsq
rout
macaqu
model
observ
higher
cellular
humor
respons
hiv
dna
vaccin
includ
plasmidencod
electropor
compar
idsq
inject
alon
induc
respons
mediat
therefor
skin
electropor
may
import
immun
approach
larger
anim
model
pig
also
use
xenotransplant
pig
regard
nextbest
sourc
replac
organ
porcin
organ
similar
size
human
counterpart
howev
human
immun
system
recognis
pig
organ
foreign
recent
problem
address
genet
modif
pig
alter
antigen
display
cell
surfac
one
major
barrier
pighuman
organ
transplant
particular
type
sugar
molecul
gal
ad
protein
surfac
pig
cell
human
cell
attempt
made
reduc
amount
sugar
express
antibodi
inhibit
enzym
galactosyltransferas
present
pig
use
addit
enzym
modifi
lehn
cowork
report
transfect
foetal
sheep
airway
utero
use
guanidiniumcholesterol
cation
lipid
gene
therapi
reduc
rejectionmedi
damag
hold
promis
novel
therapeut
strategi
corneal
transplant
donor
cornea
easili
manipul
ex
vivo
prior
transplant
corneal
endothelium
major
target
human
corneal
graft
reject
cell
essenti
postmitot
damag
repair
cell
divis
sheep
use
model
respect
ovin
endotheli
cell
amitot
absenc
topic
immunosuppress
corneal
allograft
becom
spontan
vascular
undergo
irrevers
reject
week
postop
manner
clinic
histolog
similar
human
corneal
graft
reject
therefor
particularli
use
hors
good
model
osteoarthr
diseas
occur
natur
speci
osteoarthr
oa
hors
human
signific
social
econom
problem
adenoviralmedi
gene
transfer
use
investig
therapeut
effect
result
intraarticular
overexpress
equin
receptor
antagonist
gene
establish
model
equin
osteoarthr
mimic
clinic
osteoarthr
vivo
deliveri
equin
ilira
gene
led
elev
intraarticular
express
receptor
antagonist
approxim
day
result
signific
improv
clinic
paramet
pain
diseas
activ
preserv
articular
cartilag
benefici
effect
histolog
paramet
synovi
membran
articular
cartilag
hors
osteochondr
fragment
creat
one
randomli
select
intercarp
joint
produc
experiment
oa
opposit
joint
serv
control
fig
fourteen
day
surgeri
receiv
viral
particlesjoint
dilut
gey
balanc
salt
solut
gbss
joint
lesion
opposit
nonfrag
joint
receiv
similar
volum
gbss
clinic
examin
hors
show
therapeut
express
significantli
decreas
sign
joint
pain
measur
degre
lame
nonhuman
primat
model
preclin
gene
vector
safeti
efficaci
trial
perform
macaqu
model
rhesu
macaqu
macaca
mulatta
owl
monkey
aotu
trivirgatu
common
marmoset
callithrix
jacchu
mulatta
import
model
human
diseas
research
affymetrix
rhesu
macaqu
genom
array
allow
simultan
interrog
mulatta
transcript
sirna
use
togeth
hematopoiet
stem
cell
transplant
stabli
modul
gene
express
nonhuman
primat
therefor
potenti
treat
blood
diseas
eg
coreceptor
cc
motif
chemokin
receptor
select
model
examin
feasibl
longterm
stabl
downregul
cellular
target
gene
sirna
ideal
target
essenti
infect
strain
dispens
normal
human
downregul
sirna
demonstr
protect
primari
human
lymphocyt
cultur
tropic
infect
although
effect
inhibit
infect
observ
cytotox
lymphocyt
correl
sirna
express
level
howev
use
weaker
promot
rather
promot
express
shrna
reduc
toxic
potenc
sirna
also
attenu
importantli
appar
advers
effect
observ
use
lentiviralmedi
sirna
deliveri
hematopoiet
stem
cell
differenti
cell
level
subset
phenotyp
gross
measur
lymphocyt
activ
effort
improv
dna
vaccin
immun
potenc
electropor
emerg
method
pdna
deliveri
target
tissu
howev
studi
examin
use
technolog
deliv
plasmid
vaccin
skin
detail
hirao
et
al
report
effect
electropor
dna
vaccin
potenc
gene
deliveri
use
skin
target
tissu
pig
macaqu
model
intradermalsubcutan
rout
work
experiment
psycholog
univers
cambridg
eslamboli
et
al
investig
therapeut
potenti
glial
cell
linederiv
neurotroph
factor
gdnf
parkinson
diseas
use
raav
express
gdnf
deliveri
system
common
marmoset
efficaci
like
depend
sustain
deliveri
therapeut
amount
target
area
without
affect
function
normal
dopamin
da
neuron
unilater
intrastriat
inject
raav
result
express
low
level
gdnf
ngmg
tissu
provid
approxim
protect
nigral
da
neuron
project
striatum
hemispher
deliv
continu
low
level
gdnf
striatum
approxim
threefold
baselin
suffici
provid
optim
function
outcom
owl
monkey
trivirgatu
serv
standard
nonhuman
primat
model
herp
simplex
infect
highli
suscept
enceph
owl
monkey
howev
expens
difficult
obtain
difficult
maintain
captiv
thu
greatli
hamper
effici
preclin
gene
therapi
trial
brain
tumour
use
vector
worker
harvard
medic
school
therefor
recent
compar
suscept
common
marmoset
c
jacchu
owl
monkey
model
intracerebr
inocul
wildtyp
fstrain
common
marmoset
consist
succumb
earlier
viral
enceph
owl
monkey
common
marmoset
least
suscept
intracerebr
hsvinfect
owl
monkey
therefor
serv
valid
reliabl
experiment
model
import
preclin
safeti
test
hsvbase
therapeut
viral
vector
construct
brain
safe
effici
use
hsvbase
vector
deliv
gene
potenti
therapeut
benefit
cn
requir
effect
disabl
inactiv
viral
gene
requir
lytic
growth
virus
lack
function
gene
requir
growth
cell
type
requir
growth
nondivid
cell
type
effici
deliv
marker
gene
rodent
primat
cn
rel
minim
damag
virus
paradox
deliv
gene
much
higher
effici
less
disabl
singl
mutant
lack
alon
produc
less
damag
vivo
thu
offer
platform
develop
vector
suffici
safe
ultim
use
human
gene
therapi
autoimmun
diseas
eg
rheumatoid
arthriti
multipl
sclerosi
human
treat
gene
therapi
safeti
efficaci
use
vector
must
test
valid
experiment
model
monkey
eg
rhesu
macaqu
common
marmoset
model
start
investig
nonhuman
primat
model
use
evalu
safeti
efficaci
therapeut
gene
therapi
initi
clinic
trial
human
aim
hibino
et
al
focuss
small
new
world
monkey
common
marmoset
target
preclin
model
suscept
transduct
retrovir
vector
marmoset
underw
transplant
autolog
peripher
blood
progenitor
cell
pbpc
transduc
retrovir
vector
carri
multidrug
resist
gene
demonstr
small
nonhuman
primat
use
model
evalu
gene
transfer
method
target
hematopoiet
stem
cell
develop
therapeut
agent
emerg
infecti
diseas
eg
sever
acut
respiratori
syndrom
sar
viral
infect
sirna
exemplifi
power
new
technolog
potent
sirna
inhibitor
sar
coronaviru
scv
vitro
evalu
efficaci
safeti
rhesu
macaqu
mulatta
sar
model
use
clinic
viabl
deliveri
compar
three
dose
regimen
consist
show
sirnamedi
antisar
efficaci
either
prophylact
therapeut
regimen
mgkg
accumul
dosag
sirna
show
sign
sirnainduc
toxic
result
suggest
clinic
investig
warrant
illustr
prospect
sirna
enabl
massiv
reduct
develop
time
new
target
therapeut
agent
huntington
diseas
hd
neurolog
disord
caus
genet
mutat
gene
characterist
progress
cell
death
striatum
cortex
accompani
declin
cognit
motor
psychiatr
function
anim
model
hd
provid
insight
diseas
patholog
outcom
therapeut
strategi
discoveri
huntingtin
mutat
led
creation
newer
model
incorpor
similar
genet
defect
model
includ
transgen
knockin
rodent
repres
hd
progress
patholog
even
recent
model
use
viral
vector
encod
gene
mutat
specif
area
brain
may
use
nonhuman
primat
difficult
produc
genet
model
speci
critic
assess
anim
model
appropri
certain
type
polynucl
acid
deliveri
studi
specif
regard
make
appropri
select
still
depend
upon
diseas
state
investig
whilst
sure
vast
major
anim
model
use
laboratori
mice
rat
well
rehears
argument
small
easi
work
inexpens
keep
gener
time
short
larg
litter
allow
control
breed
programm
howev
part
short
lifespan
murin
model
may
fail
reproduc
authent
human
diseas
process
therefor
longitudin
studi
still
need
perform
larg
anim
model
dog
cat
sheep
gener
larg
anim
model
longer
lifespan
physiolog
paramet
eg
immun
system
size
make
similar
human
murin
model
address
question
ethic
certainli
cost
use
larger
anim
model
allow
diseas
state
model
accur
rodent
model
diseas
even
natur
occur
eg
gene
therapi
evalu
brain
cat
affect
amd
dog
suffer
earli
sever
visual
impair
similar
seen
human
leber
congenit
amaurosi
lca
pig
use
prevent
porcin
footandmouth
diseas
studi
human
heart
diseas
hors
natur
develop
arthriti
even
choos
move
fish
initi
model
quit
rightli
cover
ethic
issu
murin
model
advoc
zebrafish
insignific
model
rather
highlight
fish
model
may
enabl
use
biolog
data
collect
certain
research
area
regard
skin
pigment
deaf
cancer
studi
especi
stress
fish
relev
eas
product
embryo
look
vivo
singl
cell
resolut
cellular
genet
basi
diseas
phenotyp
high
resolut
routin
studi
zebrafish
medaka
keenli
awar
import
refin
experi
reduct
total
number
anim
use
replac
anim
cell
line
comput
model
awar
publish
exampl
translat
one
model
anoth
anim
use
model
studi
treatment
hypothesi
specif
diseas
alway
need
verifi
hypothesi
human
clinic
trial
human
rodent
inde
anim
includ
rabbit
dog
cat
monkey
ape
roughli
number
nucleotid
genom
three
billion
bp
similar
number
gene
whilst
number
human
gene
without
clear
mous
counterpart
vice
versa
may
significantli
larger
total
nevertheless
novel
gene
may
play
import
role
determin
speciesspecif
trait
function
http
wwwornlgovsci
techresourceshumangenomefaqcompgenshtml
context
known
inherit
human
diseas
singl
nucleotid
chang
lead
inherit
sickl
cell
diseas
cystic
fibrosi
breast
cancer
singl
nucleotid
chang
alter
protein
function
deleteri
major
morpholog
differ
likewis
occur
chang
gene
differ
posit
code
sequenc
might
harm
although
similar
mammal
subtl
chang
gene
altern
splice
posttransl
modif
differ
speci
make
part
forget
environ
complex
near
futur
techniqu
gene
therapi
rnai
becom
simpler
access
societi
need
deal
complex
ethic
question
one
question
relat
possibl
genet
alter
human
egg
sperm
reproduct
cell
pass
gene
futur
gener
anoth
question
relat
potenti
enhanc
human
capabl
eg
genet
intervent
improv
memori
intellig
although
germlin
gene
therapi
genet
enhanc
potenti
produc
benefit
possibl
problem
procedur
correctli
widespread
concern
germlin
gene
therapi
would
forev
chang
genet
makeup
individu
descend
thu
human
gene
pool
would
perman
affect
although
chang
would
presum
better
error
technolog
judgment
could
farreach
consequ
case
genet
enhanc
concern
manipul
could
becom
luxuri
avail
rich
power
also
fear
widespread
use
technolog
could
lead
new
definit
normal
would
exclud
individu
exampl
mere
averag
intellig
research
human
genom
project
hgp
recogn
inform
gain
would
profound
implic
individu
famili
societi
ethic
legal
social
implic
elsi
research
program
establish
part
hgp
address
issu
elsi
research
program
promot
basic
appli
research
implic
genet
genom
research
individu
famili
commun
http
wwwornlgovscitechresourceshuman
genomemedicinegenetherapyshtml
diseas
current
view
candid
gene
therapi
caus
mutat
result
absenc
malfunct
particular
protein
eg
enzym
defici
miss
ion
channel
result
dysregulationfailur
control
cell
growth
ie
cancer
gene
therapi
studi
correct
gene
insert
genom
replac
abnorm
diseasecaus
gene
genet
approach
also
use
reveal
new
target
therapi
recent
work
inflamm
strain
mice
uncov
potenti
new
target
antiasthma
research
understand
fulli
treat
genet
diseas
patient
use
authent
anim
model
requir
studi
ethic
reason
lack
human
volunt
possibl
speci
anim
use
gene
therapi
studi
widespread
highlight
review
select
basi
anim
similar
clinic
sign
affect
human
demonstr
similar
genet
mechan
underli
diseas
speci
size
weight
metabol
thu
mani
excel
anim
model
avail
investig
target
diseas
use
new
technolog
gene
therapi
rnai
